Annovis Bio Announces Positive Phase 2 Data – Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson’s Patients

By WebmasterMarch 16, 2021November 1st, 2024No Comments

Annovis Bio Announces Positive Phase 2 Data – Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson’s Patients

Previous PostArchCare Delivers PACE Participants Seamless, Free Transportation
Next PostAnnovis Bio Signs GMP Manufacturing Agreement to Support Planned Late-Stage Studies